NAPROGENIX, INC.
Lexington, KY · Biotech · Private
Lobinaline and lobinaline N-oxide molecules, atypical dopamine transporter inhibitors for substance use disorder treatment
naprogenix.com →- Grants
- $11M
- 17 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 1
- 1 granted · 0 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Selection-driven plant metabolites for treatment of CNS diseases | $98,469 | |
| Federal grant | Department of Health and Human Services · Phase II · Mutant transgenic plant cells as a novel source of drugs | $455,773 | |
| Federal grant | Department of Health and Human Services · Phase II · Harvesting specific plant metabolites from hairy root cultures using magnetized nanoparticles | $530,326 | |
| Federal grant | Department of Health and Human Services · Phase II · Harvesting specific plant metabolites from hairy root cultures using magnetized nanoparticles | $1,029,017 | |
| Federal grant | Department of Health and Human Services · Phase II · Mutant transgenic plant cells as a novel source of drugs | $489,617 | |
| Federal grant | Department of Health and Human Services · Phase II · Harvesting specific plant metabolites from hairy root cultures using magnetized nanoparticles | $498,691 | |
| Federal grant | Department of Health and Human Services · Phase I · Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | $231,474 | |
| Federal grant | Department of Health and Human Services · Phase I · Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | $231,474 | |
| Federal grant | Department of Health and Human Services · Phase II · Mutant transgenic plant cells as a novel source of drugs | $104,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | $890,494 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | $2,972,532 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | $140,059 | |
| Federal grant | Department of Health and Human Services · Phase II · Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | $624,004 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | $975,562 | |
| Federal grant | Department of Health and Human Services · Phase II · Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | $617,521 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel modulators of the dopamine transporter for alcohol and nicotine use disorders | $966,417 | |
| Federal grant | Department of Health and Human Services · Phase II · Mimicking synuclein toxicity in plant cells to identify novel neuroprotective leads | $617,512 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2245 | AVEXEGEN THERAPEUTICS INC. | — | — |
| 2246 | CELLF-BIO LLC | — | — |
| 2247 | NOUR HEART, INC. | — | — |
| 2248 | NAPROGENIX, INC. | — | — |
| 2249 | BRIDGENE BIOSCIENCES, INC. | — | — |
| 2250 | OpalGenix, Inc. | — | — |
| 2251 | ProDa BioTech L.L.C. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.